{
    "2021-06-18": [
        [
            {
                "time": "2023-10-10",
                "original_text": "New Zolgensma data demonstrate age-appropriate development when used presymptomatically and rapid, clinically meaningful efficacy in symptomatic children, even those with severe SMA at baseline",
                "features": {
                    "keywords": [
                        "Zolgensma",
                        "age-appropriate development",
                        "presymptomatically",
                        "clinically meaningful efficacy",
                        "severe SMA"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "none"
                }
            }
        ]
    ]
}